International Liver Congress

International Liver Congress

Source:

Barrett L, et al. Abstract THU427. Presented at: The International Liver Congress. Aug. 27-29, 2020.
O’Loan J, et al. Abstract THU419. Presented at: The International Liver Congress. Aug. 27-29, 2020.

Disclosures: Healio Gastroenterology could not confirm O’Loan’s relevant financial disclosures.
September 01, 2020
1 min watch
Save

VIDEO: No ‘hard-to-reach’ patients in HCV, just ‘hardly reached’

Source:

Barrett L, et al. Abstract THU427. Presented at: The International Liver Congress. Aug. 27-29, 2020.
O’Loan J, et al. Abstract THU419. Presented at: The International Liver Congress. Aug. 27-29, 2020.

Disclosures: Healio Gastroenterology could not confirm O’Loan’s relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this exclusive video, Joss O’Loan, MBBS, from the Hepatitis C Kombi Clinic in Brisbane, Australia, discusses two studies presented at The Digital International Liver Congress on HCV elimination programs using Epclusa.

The first study looked at the efficacy of the Epclusa (sofosbuvir/velpatasvir, Gilead Sciences) in an Australian primary care setting. Researchers found that general practitioner- and nurse-led clinics could offer care with high sustained virologic response rates.

The second study also showed that the treatment could provide high cure rates, this time among underserved patient populations, including patients experiencing mental health disorders, incarceration or homelessness in the United States, Canada and Europe.

“There’s no such thing as a hard-to-reach patient, just a hardly reached patient” O’Loan said. “These two posters really emphasize that point.”